Kenneth Plunkitt.

Vivek Y. Reddy, M.D., Derek V. Exner, M.D., M.P.H., Daniel J. Cantillon, M.D., Rahul Doshi, M.D., T. Jared Bunch, M.D., Gery F. Tomassoni, M.D., Paul A. Friedman, M.D., N.A. Mark Estes, III, M.D., John Ip, M.D., Imran Niazi, M.D., Kenneth Plunkitt, M.D., Rajesh Banker, M.D., James Porterfield, M.D., James E. Ip, M.D., and Srinivas R. Dukkipati, M.D. For the LEADLESS II Research Investigators: Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker.The protective efficacy was higher when the analysis was limited to participants who reported having taken the analysis medication within the previous 30 days, a discovering that is consistent with elevated efficacy among individuals with high adherence to study medication in various other trials of preexposure prophylaxis. We previously reported that 57 percent of our study population acquired low bone mineral density at the time of enrollment,12 and our study population may consequently have been at increased risk for loss of bone mineral density while taking TDF.